

## **EU CCA: Main features of regulatory own funds instruments and eligible liabilities instruments**

This annex has been prepared in accordance with the Part Eight of EU Capital Requirements Regulation and local regulatory requirements for own funds and eligible liabilities.

It provides a description of the main features of capital instruments issued by RBS Holdings N.V. ('RBSH N.V.'), a large subsidiary of NatWest Group.

It complements the RBSH N.V. 2025 Pillar 3 report which is published in the same location at <https://investors.natwestgroup.com/results-centre.aspx>

Assumptions on the regulatory treatment of the capital instruments described herein reflect NatWest Group interpretations of current rules.

This document is for information only and is not an offer of securities nor an invitation or recommendation to invest. No investor or prospective investor in the securities described herein should rely upon the relevant description contained in this document and NatWest Group shall not be liable for any inaccuracy or misstatement

		Included in own funds and eligible liabilities	Included in own funds and eligible liabilities	Included in own funds and eligible liabilities
		Common Equity Tier 1	Additional Tier 1	Tier 2
1	Issuer	RBS Holdings N.V.	RBS Holdings N.V.	RBS Holdings N.V.
2	Unique identifier (eg CUSIP, ISIN or Bloomberg identifier for private placement)	n/a	n/a	n/a
2a	Public or private placement	Private	Private	Private
3	Governing law(s) of the instrument	Laws of the Netherlands	Laws of the Netherlands	Laws of the Netherlands
3a	Contractual recognition of write down and conversion powers of resolution authorities	n/a	No	No
<b>Regulatory treatment</b>				
4	Current treatment taking into account, where applicable, transitional CRR rules	Common Equity Tier 1	Additional Tier 1	Tier 2
5	Post-transitional CRR rules	Common Equity Tier 1	Additional Tier 1	Tier 2
6	Eligible at solo(sub-)consolidated/ solo&(sub-)consolidated	Consolidated	Consolidated	Consolidated
7	Instrument type (types to be specified by each jurisdiction)	Shareholders Equity	Additional Tier 1	Tier 2
8	Amount recognised in regulatory capital or eligible liabilities (Currency in million, as of most recent reporting date)	EUR 1,457m	EUR 250m	EUR 150m
9	Nominal amount of instrument in 'Currency of issue'	EUR 1,457,510,000	EUR 250,000,000	EUR 150,000,000
	Nominal amount of instrument in 'Currency of reporting'	n/a	EUR 250,000,000	EUR 150,000,000
EU-9a	Issue price	n/a	n/a	n/a
EU-9b	Redemption price	n/a	n/a	n/a
10	Accounting classification	Shareholder's equity	Equity	Amortised Cost
11	Original date of issuance	30/05/1990	30/09/2024	20/12/2019
12	Perpetual or dated	Perpetual	Perpetual	Dated
13	Original maturity date	No maturity	No Maturity	20/12/2029
14	Issuer call subject to prior supervisory approval	n/a	Yes	Yes
15	Optional call date, contingent call dates and redemption amount	n/a	Issuer Call 30 September 2029 or any time thereafter/ upto 100 per cent	Issuer call 20 Dec 2024 or any Interest payment date thereafter/ upto 100 per cent
16	Subsequent call dates, if applicable	n/a	Issuer Call on any date after initial call	Issuer Call on any interest payment date after initial call
<b>Coupons / dividends</b>				
17	Fixed or floating dividend/coupon	n/a	Floating	Floating
18	Coupon rate and any related index	n/a	3month EURIBOR+4.05 per cent	3month EURIBOR+2.12 per cent
19	Existence of a dividend stopper	n/a	No	No
EU-20a	Fully discretionary, partially discretionary or mandatory (in terms of timing)	Fully discretionary	Fully Discretionary	Mandatory
EU-20b	Fully discretionary, partially discretionary or mandatory (in terms of amount)	Fully discretionary	Fully Discretionary	Mandatory
21	Existence of step up or other incentive to redeem	n/a	No	No
22	Non-cumulative or cumulative	Non-cumulative	Non-cumulative	Non-cumulative
23	Convertible or non-convertible	Non-convertible	Non-convertible	Non-convertible
24	If convertible, conversion trigger(s)	n/a	n/a	n/a
25	If convertible, fully or partially	n/a	n/a	n/a
26	If convertible, conversion rate	n/a	n/a	n/a
27	If convertible, mandatory or optional conversion	n/a	n/a	n/a
28	If convertible, specify instrument type convertible into	n/a	n/a	n/a
29	If convertible, specify issuer of instrument it converts into	n/a	n/a	n/a
30	Write-down features	No	Yes	No
31	If write-down, write-down trigger(s)	n/a	Write down trigger if the CET1 ratio of RBS Holdings N.V. on a consolidated basis or NatWest Markets N.V. on an individual basis is less than 7%	n/a
32	If write-down, full or partial	n/a	Full	n/a
33	If write-down, permanent or temporary	n/a	Permanent	n/a
34	If temporary write-down, description of write-up mechanism	n/a	n/a	n/a
EU-34a	Type of subordination (only for eligible liabilities)	n/a	n/a	n/a
EU-34b	Ranking of the instrument in normal insolvency proceedings	1	2	3
35	Position in subordination hierarchy in liquidation (specify instrument type immediately senior to instrument)	Additional Tier 1	Tier 2	Senior
36	Non-compliant transitioned features	No	No	No
37	If yes, specify non-compliant features	n/a	n/a	n/a
37a	Link to the full term and conditions of the instrument (signposting)		n/a	
	Notes: Regulatory value for a Tier 2 instrument within its last five years to maturity will be subject to straight line amortisation. Amounts reported for Additional Tier 1 and Tier 2 instruments are before grandfathering restrictions imposed by CRR.			